Damora Therapeutics (DMRA) Share-based Compensation (2020 - 2026)
Damora Therapeutics' (DMRA) quarterly Share-based Compensation came in at $8.1 million in Q1 2026, up 4435.2% YoY from $179000.0 in Q1 2025, and up 1580.75% on a QoQ basis from $483000.0 in Q4 2025.
Damora Therapeutics (DMRA) Share-based Compensation (2020 - 2026) Analysis & Trends
Damora Therapeutics (DMRA) has 7 years of Share-based Compensation data on file, last reported at $8.1 million in Q1 2026.
- Quarterly Share-based Compensation rose 4435.2% year-over-year to $8.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.0 million (up 334.77% YoY) and the FY2025 annual result came in at $15.5 million, up 378.54% from the prior year.
- Share-based Compensation grew to $8.1 million in Q1 2026, from $483000.0 in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $8.1 million in Q1 2026 to a low of $172000.0 in Q2 2025.
- A 5-year average of $1.4 million and a median of $1.3 million in 2022 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2025 — Share-based Compensation tumbled 86.83% — and 2026, when it soared 4435.2%.
- Tracing DMRA's Share-based Compensation over 5 years: stood at $1.3 million in 2022, then fell by 19.2% to $1.1 million in 2023, then slumped by 71.74% to $308000.0 in 2024, then surged by 56.82% to $483000.0 in 2025, then soared by 1580.75% to $8.1 million in 2026.
- The last three Share-based Compensation figures came in at $8.1 million (Q1 2026), $483000.0 (Q4 2025), and $904000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Damora Therapeutics | 1.92 Bn | 1.38 Bn | - | 10.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10.69 Mn |
| Jun 30, 2026 | 10.69 Mn |
| Mar 31, 2026 | 8.12 Mn |
| Mar 31, 2026 | 8.12 Mn |
| Dec 31, 2025 | 483,000.00 |
| Dec 31, 2025 | 483,000.00 |
| Sep 30, 2025 | 904,000.00 |
| Sep 30, 2025 | 904,000.00 |
| Jun 30, 2025 | 172,000.00 |
| Jun 30, 2025 | 172,000.00 |
| Mar 31, 2025 | 179,000.00 |
| Mar 31, 2025 | 179,000.00 |
| Dec 31, 2024 | 308,000.00 |
| Dec 31, 2024 | 308,000.00 |
| Sep 30, 2024 | 681,000.00 |
| Sep 30, 2024 | 681,000.00 |
| Jun 30, 2024 | 891,000.00 |
| Jun 30, 2024 | 891,000.00 |
| Mar 31, 2024 | 1.36 Mn |
| Mar 31, 2024 | 1.36 Mn |